Eltrombopag: a medical countermeasure to mitigate thrombocytopenia following myelosuppressive doses of radiationsee statement of work for more details
Ended Definitive Contract Awarded Last action
- Contract number
- HHSO100201700026C
- Awardee
-
Novartis Pharmaceuticals Corporation UEI NG61ZA8TADW3
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $16,334,775
Award facts
- Opportunity
-
- BAA16100SOL00001 Solicitation number
- Broad Agency Announcement (BAA) for the Advanced Research and Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasures for BARDA Award Notice · Posted Oct 1, 2015
- Contract value 40% obligated
-
- $16,334,774.81 Current, with exercised options
- $41,003,238.81 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- East Hanover, NJ 07936, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$2,539,496 | |
| Other Administrative Action | -$18,841,773 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $7,393,435 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $2,910,000 | |
| Change Order | $1,992,113 | |
| Supplemental Agreement for work within scope | $635,815 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $197,202 | |
| Supplemental Agreement for work within scope | $696,735 | |
| Original award | $23,890,744 |
Show all 13
About this award
The Office of the Assistant Secretary for Preparedness and Response awarded a definitive contract to Novartis Pharmaceuticals Corporation for eltrombopag, a medical countermeasure to mitigate thrombocytopenia following myelosuppressive doses of radiation, with a ceiling value of $41.0 million and an ultimate completion date of May 22, 2026. This is a firm fixed-price contract with no set-aside.
Place of performance is East Hanover, NJ. The award originated on September 14, 2017. A recent modification deobligated $2.5 million across multiple contract line items, reflecting budget management within the performance window.
In FY2021, the contract reported $2.9 million invoiced against 0.7 FTEs and 1,373 contractor hours, generating a derived government-paid rate of $2,140.52 per hour. The prime self-performed all reported labor with no subcontractors.
Quick answers
Who was awarded contract HHSO100201700026C?
HHSO100201700026C was awarded to Novartis Pharmaceuticals Corporation by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 14, 2017.
How much is contract HHSO100201700026C worth?
The government has obligated $16,334,775 on HHSO100201700026C. Its potential value, with all options, is $41,003,239.
Was contract HHSO100201700026C competed?
The extent of competition for HHSO100201700026C was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award